NEW YORK, Jan. 8, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA).
The investigation focuses on whether the Company and its executives violated federal securities laws by engaging in activities in potential violation of the Foreign Corrupt Practices Act (FCPA).
Specifically, on December 21, 2016, SeekingAlpha published an article stating that the Chairman and CEO of Sinovac, Weidong Ying, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, in order to help advance drug applications and evaluations.
Request more information now by clicking here: www.faruqilaw.com/SVA. There is no cost or obligation to you.
If you invested in Sinovac stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/SVA. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sinovac's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-sinovac-biotech-ltd-to-contact-the-firm-300387173.html
SOURCE Faruqi & Faruqi, LLP